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Abstract
In order to design strategies for eradication of HIV-1 from infected individuals, detailed insight into the HIV-1 reservoirs that
persist in patients on suppressive antiretroviral therapy (ART) is required. In this regard, most studies have focused on
integrated (proviral) HIV-1 DNA forms in cells circulating in blood. However, the majority of proviral DNA is replication-
defective and archival, and as such, has limited ability to reveal the dynamics of the viral population that persists in patients
on suppressive ART. In contrast, extrachromosomal (episomal) viral DNA is labile and as a consequence is a better surrogate
for recent infection events and is able to inform on the extent to which residual replication contributes to viral reservoir
maintenance. To gain insight into the diversity and compartmentalization of HIV-1 under suppressive ART, we extensively
analyzed longitudinal peripheral blood mononuclear cells (PBMC) samples by deep sequencing of episomal and integrated
HIV-1 DNA from patients undergoing raltegravir intensification. Reverse-transcriptase genes selectively amplified from
episomal and proviral HIV-1 DNA were analyzed by deep sequencing 0, 2, 4, 12, 24 and 48 weeks after raltegravir
intensification. We used maximum likelihood phylogenies and statistical tests (AMOVA and Slatkin-Maddison (SM)) in order
to determine molecular compartmentalization. We observed low molecular variance (mean variability #0.042). Although
phylogenies showed that both DNA forms were intermingled within the phylogenetic tree, we found a statistically
significant compartmentalization between episomal and proviral DNA samples (P,10
26 AMOVA test; P=0.001 SM test),
suggesting that they belong to different viral populations. In addition, longitudinal analysis of episomal and proviral DNA by
phylogeny and AMOVA showed signs of non-chronological temporal compartmentalization (all comparisons P,10
26)
suggesting that episomal and proviral DNA forms originated from different anatomical compartments. Collectively, this
suggests the presence of a chronic viral reservoir in which there is stochastic release of infectious virus and in which there
are limited rounds of de novo infection. This could be explained by the existence of different reservoirs with unique
pharmacological accessibility properties, which will require strategies that improve drug penetration/retention within these
reservoirs in order to minimise maintenance of the viral reservoir by de novo infection.
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Introduction
In the majority of HIV-1 infected individuals antiretroviral
therapy (ART) is able to sustain suppression of plasma viral load to
undetectable levels(,50copiesHIVRNA/mlplasma) forsustained
intervals. However, viremia resumes if treatment is interrupted.
Therefore, HIV-1 is able to persist in the face of suppressive ART.
In addition low-level residual viremia has been detected with
ultrasensitive assays that are able to measure down to several copies
of HIV RNA/ml plasma [1,2]. It has been suggested that low level
viremia in ART-suppressed patients represents release of viral
particles by long-lived latently infected CD4+ T-cells [3,4,5] or
virions produced as a result of low-level, residual viral replication
[6,7,8,9,10,11]. The nature of this residual viremia, remains poorly
understood, mainly because the very low number of virions in
plasma limits its molecular characterization [3,12,13].
Intensification protocols employing integrase inhibitors have
been used to probe the viral reservoirs that persist in ART-
PLoS Pathogens | www.plospathogens.org 1 October 2011 | Volume 7 | Issue 10 | e1002314suppressed patients. When viral integration is inhibited, the linear
viral genome, which is the precursor to the integrated provirus, is
converted to episomes [14,15]. Although sequences gleaned from
episomal DNAs could be present in both productive and non-
productive infections, integrase inhibition specifically results in
increased episome formation and since linear cDNA is a product
of reverse transcription, increases in episomal cDNA in blood cells
after starting raltegravir indicates de novo infection and blocked
integration. Because of the dynamic nature of episomes, they
harbor a higher percentage of contemporary sequences as
compared to proviral sequences that contain a higher percentage
of archival sequences. Therefore, although episomes are dead-end
products of viral replication, sequences contained within them will
also be observed in functional viral genomes. As a consequence,
characterization of the nature of episomal HIV-1 DNA during
raltegravir intensification of a suppressive HAART regimen could
provide new insights into the molecular diversity and compart-
mentalization of the viral reservoirs that persist in the face of
suppressive therapy. We previously reported that raltegravir
intensification of HAART-suppressed patients affected HIV-1
replication and immune dynamics in a large percentage of these
patients [16,17]. In order to gain further insight into the molecular
diversity, population structure, and compartmentalization of
replicative viral forms under suppressive HAART, episomal and
integrated HIV-1 DNA samples were longitudinally analyzed by
deep sequencing after intensification with raltegravir. We found
signs of molecular compartmentalization distinguishing episomal
and integrated HIV-1 DNA populations in PBMC, suggesting that
proviruses in a cellular/anatomical compartment other than those





reported raltegravir-intensification study [16,17] who had plasma
viremia below 50 HIV-1 RNA copies per ml for two years on stable
HAART. Subjects were selected based on sample availability.
Reverse-transcriptase genes from episomal and integrated HIV-1
DNA were specifically amplified and analyzed at weeks 0, 2, 4, 12,
24 and 48 following raltegravir intensification. Only viral sequences
present in $1% of the virus population were considered for further
analysis. The median number and interquartile range of episomal
HIV-1 DNA clonal sequences for patients 1 and 2 was 3,063
(2,017–3,473) and 4,040 (2,106–6,131), respectively. For integrated
HIV-1 DNA in patients 1 and 2, the median was 2,645 (1,570–
3,592) and 2,889 (2,247–4,184), respectively.
Episomal and integrated HIV-1 DNA belong to different
viral populations
We constructed a phylogenetic tree for each patient to assess if
episomal and integrated HIV-1 DNA sequences belonged to
different genetic populations or to one intermixed population. We
used aneighbor-joiningapproach,asimplementedinMEGA4[18],
to construct a phylogenetic tree for each patient with the best
evolutionary model found in jModeltest v0.1.1. Phylogenetic trees
did not show a clear cluster differentiation of both DNA forms
(Figs. 1 and 2), suggesting a lack of population structure between
both DNA samples, at least at the sequence composition level. Even
when sequences do not clearly group into separate branches,
statistical analysis can still reveal differences in sequence diversity
between different HIV populations [12,19,20]. Therefore, to better
assess possible compartmentalization, we performed a population
structure test based onthe analysisof molecularvariance(AMOVA)
on pairwise genetic distances and percentages of the presence of
each clone in each population [21]. This test showed different ratios
of population structure (FST) between episomal and integrated
sequences (Table 1), which all were statistically significant (P,10
26)
in both patients. As different tests of population structure can yield
contradictory results, we performed a recommended conservative
analysis [22] usinga complementary compartmentalization test.We
applied the Slatkin-Maddison test [23], which is based only on tree
topology comparison. Consistent with the AMOVA test, the results
of the Slatkin-Maddison analysis showed only a few migration
events between episomal and integrated samples: 12 out of 55
possible migration events, and 9 out of 46 possible migration events
in patients 1 and 2 respectively (P=0.001) (Table 1). In addition, we
obtained similar results when a longitudinal point-by-point
comparison was performed between both DNA viral forms, except
for three samples where the migration events had a high probability
of being random (Table 1). Interestingly, two of these three samples
were taken at the study baseline, i.e. right before HAART
intensification with raltegravir. Overall, these results point to
statistically significant compartmentalization between episomal
and integrated DNA samples and suggest that they belong to
different viral populations.
Non-chronological temporal compartmentalization
within episomal and integrated HIV-1 viral forms
We next assessed whether longitudinal episomal and integrated
DNA sequences had a temporal structure. Firstly, we constructed a
separate neighbor-joining phylogenetic tree for each patient and
each viral DNA form (Fig. 3 and 4). Phylogenies showed evidence
of a temporal structure within episomal and integrated viral DNA
forms across different time-points. Temporal structure was more
Author Summary
In the majority of HIV-1 positive patients, antiretroviral
therapy (ART) effects a sustained reduction in plasma
viremia to below detectable levels. Despite this, replication
competent viruses persist and fuel viremia if antiretroviral
treatment is interrupted. This viral persistence stands in
the way of viral eradication through ART. While this ability
to persist in the face of therapy is generally considered to
be attributable to a reservoir of latently infected cells,
there is debate as to how this reservoir is maintained and
in particular, whether there is replenishment of the
reservoir by low level, residual replication. Novel antiviral
agents targeting the viral integrase offer tools to explore
the viral reservoirs that persist in the face of ART and we
have shown that raltegravir perturbs these reservoirs as
evidenced by an accumulation of episomal DNA upon
rategravir intensification (Buzon et al., 2010). Through
‘‘deep sequencing’’ technology, we have longitudinally
analyzed the genotypes of HIV episomes and integrated
HIV DNA to evaluate whether they represent interrelated
sequences or whether they have distinct origins. Statistical
methods showed molecular compartmentalization, among
and within episomal and integrated HIV-1 DNA samples,
and suggest that episomal DNA in PBMC originates from a
cellular/anatomic reservoir that is not revealed by
sequencing of proviral DNA in PBMC in this study. These,
and other data, suggest that ongoing replication, which
can be blocked by adding raltegravir, occurs from
proviruses that are genetically distinguishable from those
detected at .1% frequency in these circulating blood
cells.
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integrated samples of patient 1 (Fig. 3b). However, a clear sign of
temporal structure was difficult to observe in the remaining
phylogenetic trees (Fig. 3a and 4b). Therefore, we used the
AMOVA and Slatkin-Maddison tests to again assess the presence
of temporal population structure within each viral DNA form.
AMOVA showed that all longitudinal comparisons within
episomal and integrated samples were significantly different
(P,10
26) indicating different temporal population structures
(Tables 2–5). Statistically significant Slatkin-Maddison results were
partly consistent with those detected by AMOVA (Tables 2–5).
Discrepancies between both tests might be due to the large
number of sequences with the same haplotype (sometimes present
in both compartments). In fact, the performance of the Slatkin-
Maddison test might be limited when there is a combination of
relatively short sequence, high depth and low within-patient
diversity [23], as in this case.
Our results revealed that in both episomal and integrated HIV-
1 DNA samples, distinct genetic populations appeared at different
time-points, suggesting that the appearance of each viral DNA
form in blood could be the result of stochastic mobilization of
different HIV-infected cells. This effect has been observed for
residual viremia [12] and for different populations of CD4
+ T-cells
[7]. Furthermore, we did not observe any signs of evolution across
longitudinal samples within episomal DNA or within integrated
viral forms (Fig. 3 and 4). We found temporal variation but no
evidence of continued evolution. Of note, patient 1’s viruses
harbor the mutation M184I in the reverse transcriptase of the
integrated HIV sequences from weeks 0 and 2 (but not from weeks
4 or 24), which is associated to resistance to lamivudine and
emtricitabine. This patient was under a regimen containing
tenofovir, lamivudine, lopinavir, ritonavir and raltegravir. In
contrast episomal sequences from weeks 0, 2 and 4 were wild type,
which suggest that 2LTR circles were generated in a different
cellular/anatomical compartment that is possibly less accessible to
lamivudine.
Different proportions of clonal sequences, rather than
different sequences, determine population structure in
patients under suppressive HAART
A population structure can occur at two levels: (i) different
composition at the sequence level and (ii) different proportions of
specific haplotypes. Therefore, the percentage of each clonal
sequence of each DNA sample was represented (Fig. 3c–d and
Fig. 4c–d). The results show that some haplotypes were shared
among and within HIV-1 viral DNA forms, but unique haplotypes
were also found. Moreover, when sequences were shared, the
percentage of each haplotype was different between samples. This
observation, together with the low molecular variability found in
each sample (Table 1), suggests that patients under suppressive
HAART have a limited variability in viral DNA sequences and
that the presence and relative proportion of each clonal sequence
might determine whether a population structure exists.
Discussion
Previous reports have shown evidence of compartmentalization
between residual plasma viremia and proviruses in fractionated
and unfractionated PBMC [12]. However, this is the first time that
episomal cDNA and integrated HIV-1 DNA genomes have been
extensively compared. We found a statistically significant com-
partmentalization between episomal and integrated DNA samples
in PBMC suggesting that, as with residual plasma viral RNA,
episomal HIV-1 DNA forms are genetically distinct from proviral
genomes and that they encompass two different genetic popula-
tions. In addition we have shown that in both episomal and
integrated HIV-1 DNA samples, distinct genetic populations
appeared, in a non-chronologic manner, at different time points.
Longitudinal, non-chronological population structure between and
within samples was detected in both circular episomal and proviral
HIV-1 DNA viral forms. One explanation for our findings is that
episomal and proviral sequences were generated in distinct cell
types or anatomical compartments, possibly with different
pharmacological penetration profiles. The detection of both
DNA forms could result from stochastic mobilization from tissues
to blood of a few infected cells, as their low molecular variance
suggests. However, the labile nature of episomal DNA and its
specific dynamics after raltegravir intensification [16] implies that
the infection events that generated them occur in a pharmacolog-
ically privileged site (because the infections that generated them
are occurring in the face of RT inhibitors) yet that is still accessible
to raltegravir. A recent report shows that ileum may support
ongoing productive infection in some patients on HAART, even if
the contribution to plasma RNA is not discernible. In fact,
raltegravir intensification contributed to a decrease in the cell-
associated HIV RNA in this anatomic site relative to other gut sites
or PBMC, suggesting that gut sites differ with respect to
penetration by antiretroviral drugs, immunologic environments
or the composition of CD4
+ T cell populations [24]. Alternatively,
our results might also suggest that cells containing these
transiently-increased episomes might result from new infections
with replication-competent viruses originating from rare provirus-
es not detectable in peripheral blood mononuclear cells, and that
these episomes have had their integration blocked by raltegravir.
The lack of population structure or evolution in integrated HIV-
1 genomes is best explained by the fact that proviruses are
predominantly defective and archival. Although the provirus is the
molecular precursor for all virions, only a very small percentage of
proviruses are replication competent and only a small percentage
of these would exist in a latent state- one capable of producing
replication-competent virions. Therefore, temporal structure
might simply be a result of continuous seeding of new cells over
time. In this regard, multiple monotypic HIV-1 sequences have
been observed across the uterine cervix and in blood, presumably
as a result of the proliferation of cells harboring proviruses [25].
Although the origin of these cells with integrated HIV-1 DNA in
our study remains unknown, forthcoming genotypic analysis across
cell subpopulations in blood and tissues may cast light on this issue.
Memory CD4
+ T cells are thought to be a stable reservoir of HIV
infection [26,27,28,29,30,31]. The transient increases in 2LTR
circles in PBMC from patients during early HAART in the
absence of raltegravir, has recently been associated with the
redistribution of 2LTR-enriched memory CD4+ T-cells from
lymphoid tissues due to short-term decreases in immune activation
[32]. In our study, changes in immune activation occurred more
slowly. As such, distinct mechanisms appear to account for the
Figure 1. Phylogenetic tree of patient 1. A neighbor-joining approach, as implemented in MEGA4, was used to construct a phylogenetic tree
with the best evolutionary model found in jModeltest v0.1.1. Circles and squares represent longitudinal episomal and integrated DNA sequences,
respectively. Legends of phylogenetic trees represent weeks available for further analysis. Sizes of the symbols represent the different percentages of
clonal sequences. 1,000 bootstrap replicates were performed; only values greater than 50% are shown at tree nodes.
doi:10.1371/journal.ppat.1002314.g001
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PLoS Pathogens | www.plospathogens.org 4 October 2011 | Volume 7 | Issue 10 | e1002314Figure 2. Phylogenetic tree of patient 2. A neighbor-joining approach, as implemented in MEGA4, was used to construct a phylogenetic tree
with the best evolutionary model found in jModeltest v0.1.1. Circles and squares represent longitudinal episomal and integrated DNA sequences,
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shown that the majority of a highly specialized subset of antigen-
specific memory CD4
+ T cells in mice were found to reside in a
resting state in the bone marrow, surviving in close proximity to
IL-7-secreting stromal cells [33]. Coincidently, IL-7 also induces
homeostatic proliferation of human central memory CD4
+ T cells
without causing viral reactivation [34]. Therefore, the different
population structure within integrated DNA, which is not
coincident with the episomal DNA population, could be explained
by the re-activation and mobilization of memory CD4
+ T-cells
from different niches in bone marrow without subsequent viral
production, and could be a consequence of cellular rather than
viral dynamics. Previous studies have examined rebounding
viremia following treatment interruption and suggested that
emerging viral variants result from the stochastic reactivation of
different HIV-1 infected cells [4,35,36,37]. Finally, infectious
events during HAART can occur in multiple, temporary, small
and locally scattered bursts [38] consistent with our observed
genotypic compartmentalization. In addition, we observed that the
cell-associated HIV proviral DNA remained relatively stable (Fig.
S1) despite the large shifts in sequence populations observed
during the study. This would not only mean that newly infected
cell populations had undergone expansion but that other
populations contracted at the same time. It is tempting to
speculate that these dynamics might be consistent with the
continuous trafficking between blood and tissues (preferentially
lymphoid tissue) of stochastically activated antigen-specific mem-
ory CD4+ T-cells. We believe that it is unlikely that the results
obtained reflect limited sampling, because we detected different
proportions of shared haplotypes at different longitudinal time
points (Fig. 1c,d and Fig. 2c,d). Sequence diversity restrictions due
to sampling limitations would be reflected by either a completely
different population structure or by invariable shared haplotypes
in different samples. Moreover, at least in some time points, there
is quite a large number of unique haplotypes (.1%), suggesting
good depth.
Proviral HIV sequences are currently thought to be representa-
tive of archival HIV infection in an infected patient. Based on this
hypothesis, sources of residual viremia other than CD4
+ T-cells
have been postulated as long-lived viral reservoirs [3]. Our
observation that longitudinal detection of proviral genomes is
dynamic in patients on HAART is important because it points to
some limitations in the conclusions drawn from cross-sectional
studies comparing HIV sequences in plasma and circulating T-cells.
Our results collectively suggest the presence of a chronic viral
reservoirinwhich thereisstochasticreleaseofinfectiousvirusand in
which there are limited rounds of de novo infection. This could be
explained by the existence of a limited cellular/anatomic reservoir
in which de novo infection continues during HAART because some
antiretroviral drugs do not effectively inhibit replication in this
compartment.However,evidencethatepisomestransientlyincrease
after raltegravir intensification suggests that this cellular/anatomic
reservoir may be accessible to raltegravir, in contrast to other drugs.
If proven in future work, the concept that ongoing replication
during successful HAART originates from proviruses that are not
detectable in peripheral blood mononuclear cells has important
respectively. Legends of phylogenetic trees represents weeks available for further analysis. Size of the symbols represent the different percentages of
clonal sequences. 1,000 bootstrap replicates were performed; only values greater than 50% are shown at tree nodes.
doi:10.1371/journal.ppat.1002314.g002
Table 1. Population structure analysis.
Mean Diversity AMOVA Slatkin-Maddison Test
Patient Time PEpi PInt FST P-value Migrations Prob
*
1 W0 0.0091 ,0.0001 0.7287 ,10
26 1 0.105
W2 0.0019 ,0.0001 0.9889 ,10
26 1 0.056
W4 0.0265 0.0063 0.1891 ,10
26 2 0.026
W12 0.0313 0.0019 0.8412 ,10
26 2 0.033
W24 0.0422 0.0198 0.5160 ,10
26 4 0.578
Total 0.0278 0.0201 0.1684 ,10
26 12 0.001
2 W0 0.0057 0.0081 0.1679 ,10
26 5 0.584
W2 ,0.0001 0.0067 0.1092 ,10
26 1 0.058
W4 ,0.0001 0.0084 0.7680 ,10
26 1 0.057
W12 NA 0.0054 NA NA NA NA
W24 ,0.0001 NA NA NA NA NA
W48 0.0019 NA NA NA NA NA
Total 0.0076 0.0079 0.1457 ,10
26 9 0.001
Mean internal diversity for each time point and DNA source is shown for each patient. Genetic diversity (p), defined as the average number of nucleotide differences per
site between any two sequences chosen randomly from the sample population, is calculated with the best evolutionary model found in the jmodeltest Tamura and Nei
model [45]. The fixation index, FST, from the AMOVA analysis is a measure of the diversity of randomly chosen sequences within the same sub-population relative to that
found in the entire population. A zero value implies that the two populations mix freely, while a value of one implies that the two subpopulations are completely
separate. The Slatkin Maddison test uses an estimate of the number of ‘migrations’ between subpopulations to assess population structure, with smaller numbers of
migrations (for a given number of sequences) indicating more structure. Both AMOVA and the Slatkin-Maddison test calculate a p value for the null hypothesis of no
population structure by randomly permuting sequences between subpopulations; they differ as the AMOVA takes into account the frequency of each unique sequence
or haplotype, whereas the Slatkin Maddison test does not.
*Probability that a migration event is random after 10,000 resampling replicates.
NA, indicates that the test or the data is not applicable or available.
doi:10.1371/journal.ppat.1002314.t001
Molecular Characterization of HIV-1 under HAART
PLoS Pathogens | www.plospathogens.org 6 October 2011 | Volume 7 | Issue 10 | e1002314implications for the design of strategies aimed at viral eradication or
functional cure. It indicates the need to further define the limited
and covert cellular/anatomic reservoir in which ongoing HIV
replication may occur during suppressive HAART.
Materials and Methods
Ethics statement
The study was approved by the Germans Trias i Pujol hospital
review board and informed consent was obtained in writing from
study participants.
Study patients
We extensively analyzed longitudinal samples from 2 HIV-
infected patients whose plasma viral load had been suppressed to
,50 HIV-1 RNA copies/ml for 2 years on a stable HAART
regimen. Both patients had participated in a previously reported
raltegravir-intensification study [16,17] were intensification of a
three-drug suppressive HAART regimen resulted in a specific and
transient increase in episomal DNA in a large percentage of
patients. The original study was designed to compare populations of
episomal and integrated HIV-1 DNA and plasma viral RNA in 5
patients with detectable episomal DNA before raltegravir intensi-
fication. Although plasma viral load assays employed 7 ml of
plasma, we were unable to amplify viral RNA sequences for the
majority of time points nor amplify episomal and integrated HIV-1
DNA from the majority of longitudinal samples in 3 patients. For
this reason, structure comparisons between episomes and integrated
HIV-1 DNA were only possible for the 2 subjects shown in this
study. Episome and proviral DNA dynamics for both patients are
shown in Fig. S1. HAART regimens included lopinavir, ritonavir,
lamivudine, tenofovir and raltegravir for patient 1 and efavirenz,
emtricitabine, tenofovir and raltegravir for patient 2. None of the
included patients had previously been exposed to integrase
inhibitors. Peripheral blood mononuclear cells (PBMC) and plasma
samples included in this study encompassed weeks 0, 2, 4, 12, 24
and 48 after raltegravir intensification.
Nucleic acid purification
A median of 6610
7 PBMC were obtained at weeks 0, 2, 4, 12,
24 and 48 after intensification and purified by Ficoll centrifugation
and resuspended in 350 ml of P1 buffer (Qiaprep miniprep kit,
Figure 3. Phylogenetic tree and proportions of episomal and integrated HIV-1 sequences in patient 1. A neighbor-joining approach, as
implemented in MEGA4, was used to construct a phylogenetic tree with the best evolutionary model found in jModeltest v0.1.1. a. Circles represent
longitudinal episomal DNA sequences. b. Squares represent longitudinal integrated DNA sequences. Legend of phylogenetic trees represents weeks
available for further analysis. Sizes of the symbols represent the different percentages of clonal sequences. c. Longitudinal representation of the
clonal variability of each episomal sample. d. Longitudinal representation of the clonal variability of each integrated sample. Areas of pie charts in
white shading indicate sequences present with a frequency below 1%; gray shading indicates sequences with a frequency above 1% present in only
one sample throughout the study period; colors represent sequences with a frequency above 1% present in two or more samples throughout the
study period. 1,000 bootstrap replicates were performed; only values greater than 50% are shown at tree nodes.
doi:10.1371/journal.ppat.1002314.g003
Molecular Characterization of HIV-1 under HAART
PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002314Qiagen). 250 ml of cell suspensions were used for extrachromo-
somal HIV-1 DNA extraction (Qiaprep miniprep kit, Qiagen)
using a modification for the isolation of low-copy-number
plasmids. Total cellular DNA was purified from 100 ml of cell
resuspension with a standard protocol (QIAamp DNA Blood Kit,
Qiagen) as previously described [16].
Figure 4. Phylogenetic tree and proportions of episomal and integrated HIV-1 sequences in patient 2. A neighbor-joining approach as
implemented in MEGA4 was used to construct a phylogenetic tree with the best evolutionary model found in jModeltest v0.1.1. a. Circles represent
longitudinal episomal DNA sequences. b. Squares represent longitudinal integrated DNA sequences. Legend of phylogenetic trees represents weeks
available for further analysis. Sizes of the symbols represent different percentage of clonal sequences. c. Longitudinal representation of clonal
variability of each episomal sample. d. Longitudinal representation of clonal variability of each integrated sample. Areas of pie charts in white shading
indicate sequences present with a frequency below 1%; gray shading indicates sequences with a frequency above 1% present in only one sample
throughout the study period; colors represent sequences with a frequency above 1% present in two or more samples throughout the study period.
1,000 bootstrap replicates were performed; only values greater than 50% are shown at tree nodes.
doi:10.1371/journal.ppat.1002314.g004
Table 2. Temporal population structure: AMOVA test for comparison between longitudinal episomal HIV-1 DNA.
AMOVA test - Episomal HIV-1 DNA
Fst (P-value)
W0 W2 W4 W12 W24 W48












26) – 0.133 (,10
26) 0.592 (,10
26)N A









26) NA 0.965 (,10
26) –
The longitudinal comparisons of patient 1 are indicated in the upper-right hemi-matrix of the table (italics); those of patient 2 are shown in the lower-left hemi-matrix of
the table (bold).
doi:10.1371/journal.ppat.1002314.t002
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Analysis of HIV genomes from a sample containing a low copy
number of HIV, such as PBMC from patients with undetectable
viral load, can result in a high probability of resampling. The
probability of resampling is related to both the number of target
molecules during the amplification step and the number of
sequenced clones. Therefore the higher the input of target
molecules in the PCR and the higher the number of sequenced
clones, the less likely the probability of resampling [39]. In order to
avoid resampling, we extracted episomal and integrated DNA
from a median of 6610
7 PBMC to increase the number of input
molecules during the first PCR. In addition, only samples with
individual clonal sequences higher than 1,500 after deep
sequencing were considered for further analysis.
We used a two-step PCR to amplify the RT region of episomal
and integrated HIV-1 DNA. Primers Aluf and LA7 for integrated
DNA and Jct f and LA7 for episomal DNA were used as previously
described [10]. Nested PCR amplification of the RT region
(codons 150 to 250) was performed as part of the DS protocol (see
below). Nested PCR of background controls with primers DR pol f
and DR pol r [10], in parallel to 454 amplification, was carried out
to ensure that nested PCR was specific for integrated and episomal
DNA viral forms.
Deep HIV-1 sequencing
Pooled, purified PCR products were used as template to
generate a single amplicon covering codons 150 to 250 from the
RT region. The amplicon library was generated in triplicate
during 20 cycles of PCR amplification (Platinum Taq DNA
Polymerase High Fidelity, Invitrogen, Carlsbad, CA) followed by
pooling and purification of triplicate PCR products using magnetic
beads (Agencourt AMPure Kit (Beckman Coulter, Benried,
Germany) to eliminate primer-dimers. The number of molecules
was quantified by fluorometry (Quant-iT PicoGreen dsDNA assay
kit, Invitrogen, Carlsbad, CA). The quality of each amplicon was
analyzed by spectrometry using a BioAnalyzer (Agilent Technol-
ogies Inc., Santa Clara, CA). Deep Sequencing (DS) was
performed in-house on a 454 Life Science/Roche platform. The
error rate of the in-house DS technique, as inspected with 992
pNL43 clonal sequences obtained with DS under the same
conditions as those used for patient samples, was 0.07% (0.13%),
which is close to previous reports [40]. This mismatch rate
corresponds to a variability rate of 1.69610
-5, within the range of
expected PCR error. The 99th percentile of mismatches would
establish the threshold for nucleotide errors in 0.61%. Therefore,
we decided to include for further analysis only patient clonal
sequences present at $1% of the viral population.
Table 3. Temporal population structure: AMOVA test for comparison between longitudinal integrated HIV-1 DNA.
AMOVA test - Integrated HIV-1 DNA
Fst (P-value)
W0 W2 W4 W12 W24 W48


















26) – 0.763 (,10
26)N A
W24 NA NA NA NA – NA
W48 NA NA NA NA NA –
The longitudinal comparisons of patient 1 are indicated in the upper-right hemi-matrix of the table (italics); those of patient 2 are shown in the lower-left hemi-matrix of
the table (bold).
doi:10.1371/journal.ppat.1002314.t003
Table 4. Temporal population structure: Slatkin-Maddison test for comparison between longitudinal episomal HIV-1 DNA.
Slatkin-Maddison test - Episomal HIV-1 DNA
Migrations (Probability)
W0 W2 W4 W12 W24 W48
W0 – 1/4 (0.006) 5/5 (0.698) 6/6 (0.810) 2/4 (0.028) NA
W2 1/3 (0.025) – 1/4 (0.008) 1/4 (0.001) 1/3 (0.015) NA
W4 1/3 (0.017) 1/2 (0.097) – 6/7 (0.999) 3/4 (0.231) NA
W12 NA NA NA – 4/5 (0.496) NA
W24 1/3 (0.018) 1/2 (0.099) 1/2 (0.099) NA – NA
W48 3/4 (0.445) 1/3 (0.058) 1/3 (0.058) NA 1/3 (0.029) –
The longitudinal comparisons of patient 1 are indicated in the upper-right hemi-matrix of the table (italics); those of patient 2 are shown in the lower-left hemi-matrix of
the table (bold).
doi:10.1371/journal.ppat.1002314.t004
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454 DNA amplicon sequences were aligned with an HXB2
reference sequence using Muscle v3.7 [41] and an independent
alignment for each DNA, time-point and patient was built. In order
toincreasethenumberofsequencesforfurtheranalysisandtoavoid
sequencing errors produced at the end of the sequencing run, we
extracted from codon 50 to 209 from each of the sequences
obtained with DS. Technical errors of the DS technique drive the
introduction of indeterminations (introducing N instead of A, T, G
or C) into the sequences. These indetermination were substitute by
gaps. An in-house method was used to merge clonal sequences into
unique sequences. Only clonal sequences present at $1% of the
clonalpopulationwereused.Alignmentsareavailableuponrequest.
Phylogenetic analysis
jModeltest v0.1.1 [42] was used to infer the best phylogenetic model
to explain the alignment sequence evolution. This program is able to
implement a discrete gamma distribution (C)w h i c hm o d e l st h e
heterogeneity rate among sites. A neighbour-joining approach, as
implemented in MEGA4 [18], was used to construct a phylogenetic
tree with the best evolutionary model found in jModeltest v0.1.1.
Population structure analysis
In order to detect differences in sequence composition between
episomal and integrated DNA at different time-points, we
performed two analyses, (i) an analysis of molecular variance
(AMOVA) as implemented in the Arlequin software package [21],
which is based on pairwise genetic distances and percentage of
presence of each clone at each population, and (ii) a tree based
topology method, the Slatkin-Maddison test [23] as implemented
in HYPHY [43]. The Slatkin-Maddison tests involve estimating
the number of migrations between populations, and determining
whether the estimated number of migrations is less than expected
if there were no compartmentalization. As the maximum possible
number of migrations depends on the number of sequences
analyzed from each compartment, a randomization test is
performed to estimate a p value to assess the significance of
compartmentalization. This approach has previously been used to
study differences in sequence diversity between different HIV
populations [12,19,20]. AMOVA is a genetic distance-based test
where the frequency of a sequence variant (haplotype) i in the
organ j, xij, can be expressed as xij=x+ ai + bij, where ai and bij are
episomal or integrated DNA and the haplotype within-DNA
specific effects, respectively. These two factors have associated
variances s2
a and s2
b that can be described as total variance among
haplotypes as s2
T. The FST index measures the population





and it can be estimated from the usual partition of total variance
into its components in a nested analysis of variance (ANOVA)
[44]. We carried out AMOVA analysis by computing FST with a
distance matrix obtained from Arlequin program using the best
evolutionary model found by jModeltest.
Supporting Information
Figure S1. Longitudinal dynamics of 2-LTR circles and
total HIV-1 DNA during the study.
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